Applied Therapeutics Inc (APLT)

APLT0.37 +9.95%
  • O

    0.34

  • H

    0.37

  • L

    0.34

  • C

    0.37

  • V

    1953k

15分钟延迟

交易条款

交易时间 (UTC)
星期一: 11:00 - 00:00
星期二 - 星期五: 00:00 - 00:30, 11:00 - 00:00
星期六: 00:00 - 00:30

关于

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). It is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.

http://www.appliedtherapeutics.com/
х
风险警告: 在金融市场上交易存在风险。投资产品可能会升值也可能会贬值,投资者可能会损失所有的本金。在涉及有杠杆的产品时,损失可能会大于初始本金。在金融市场上交易的风险信息可以在此查看 全面风险披露
联系我们暴跌